Nkarta, Inc. Restructuring Reserve
Nkarta, Inc. (NKTX) had Restructuring Reserve of $0 as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities
us-gaap:RestructuringReserve · last filed 2026-08-10
- 2026-06-30: Restructuring Reserve $0.00.
- 2026-03-31: Restructuring Reserve $0.00.
- 2025-12-31: Restructuring Reserve $145.00K.
- 2025-09-30: Restructuring Reserve $668.00K.
| Period end | Restructuring Reserve |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-10 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 |
| 2025-12-31 | $145.00K 10-Q · filed 2026-08-10 |
| 2025-09-30 | $668.00K 10-Q · filed 2025-11-10 |
| 2025-06-30 | $1.36M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $3.29M 10-Q · filed 2026-08-10 |
| 2024-12-31 | $0.00 10-Q · filed 2026-08-10 |
| 2023-12-31 | $400.00K 10-K · filed 2025-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |